INTRODUCTION {#s1}
============

Panel-based, somatic mutational profiling of tumors has become routine in the selection of therapies for precision oncology. Several reports have shown that BRCA1 or BRCA2 dysfunction sensitizes cells to PARP inhibition ([@R1],[@R2]). Several PARP inhibitors have been approved as monotherapies for *BRCA1/2*-mutated ovarian cancer and *BRCA1/2*-mutated, metastatic triple-negative breast cancer ([@R3]--[@R5]). In addition, mutations in other homologous recombination repair (HRR) genes have been associated with PARP inhibitor sensitivity ([@R6]). Early investigation has begun into the use of PARP inhibitors for other tumor types ([@R7],[@R8]). However, the role of these mutations in colorectal cancer (CRC) and endometrial cancer (EC) is unknown.

Molecular profiling has also been used to identify subtypes of cancers responsive to immunotherapy. Microsatellite unstable (MSI-H) CRCs and ECs, and more recently microsatellite stable (MSS) hypermutant tumors (often *POLE*-mutated), have demonstrated robust responses to immunotherapy, primarily attributed to their high neoantigen burden and strong immune infiltrates ([@R9]--[@R13]). Recent survival analyses have demonstrated *POLE*-mutated tumors to be an independent risk factor for identifying individuals who benefited from immune checkpoint inhibitors, with effects on survival similar to those seen with MSI-H tumors ([@R14]). Although low-cost methodologies such as immunohistochemistry of mismatch repair proteins and microsatellite testing exist to screen for MSI, comprehensive identification of MSS hypermutators relies on expensive tumor mutational burden assays that require sequencing of \>1 million megabases (\>400 genes) to achieve reliable results ([@R15],[@R16]). Further limiting, these tests are clinically available from only a few commercial laboratories and academic medical centers and lack standardized approaches to calculate and report out high tumor mutational burden samples. Alternatively, sequencing of the exonuclease domain of *POLE* has been embraced as a lower cost alternative by several institutions and clinical trial sponsors. However, this approach limits detection to only those hypermutators with established hotspot pathogenic mutations.

In this study, we investigated the relationship between somatic truncations in *BRCA1/2* and other HRR genes with hypermutant subtypes of CRC and EC and leveraged this unexpected observation to develop an accurate and low-cost methodology to screen for MSS hypermutators using a small number of genes already incorporated by many health care institutions for somatic profiling.

METHODS {#s2}
=======

Study populations {#s2-1}
-----------------

We performed analyses on 2,335 published samples from the CRC and uterine corpus EC (UCEC) subsets of The Cancer Genome Atlas (TCGA) PanCancer study, the MSK-IMPACT cohort (Memorial Sloan Kettering Cancer Center \[MSKCC\]) of EC and metastatic CRC ([@R17]--[@R19]). All clinical characteristics and annotated somatic mutation data were taken from the cBioPortal ([@R20],[@R21]). MSI status was unavailable for 11 samples from the TCGA samples. We determined MSI status for these samples using somatic signature analyses from Mutect2 variant call files derived from whole-exome sequencing. Samples from MSK-IMPACT were deemed MSI-H if either established by immunohistochemistry or MSIsensor. Annotated somatic mutations of CRCs and ECs analyzed by DFCI-OncoPanel-3 (Dana-Farber Cancer Institute) and ECs analyzed by MSK-IMPACT 410 and MSK-IMPACT 468 panels (N = 1,439) were also obtained from the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) v5.0 deposited on the cBioPortal ([@R22]). MSI status data were unavailable for these AACR Project GENIE samples, conservatively inferred as MSI-H by the presence of *BRAF* V600E mutations, pathogenic mutations in mismatch repair genes with variant allele frequencies approaching 0.5 suggesting germline susceptibility to Lynch syndrome, or the presence of frameshift mutations in *ACVR2A*, *TGFBR2*, or *RNF43* ([@R23]). In addition to annotated somatic mutations, nonsynonymous mutation counts were analyzed in context of the sequencing panel used.

Development and validation of a microsatellite stable hypermutator classifier {#s2-2}
-----------------------------------------------------------------------------

We devised a classifier that would return positive if 1 or more of 3 criteria were fulfilled:Tumor contained a known pathogenic exonuclease domain mutation in Polε (amino acids 268--471). The set of known pathogenic exonuclease domain mutations was defined as those annotated as pathogenic in ClinVar or previously demonstrated by functional *in vivo* validation studies ([@R24],[@R25]).The presence of a variant of unknown significance (VUS) in the exonuclease domain of Polε AND either a somatic truncating mutation (nonsense, splice site, or frameshift) in any one of 13 HRR genes (*BRCA1, BRCA2, PTEN, ATM, ATR, PALB2, MRE11, BARD1, BRIP1, RAD50, RAD51B*, *RAD51C*, and *RAD51D*) or pathogenic missense mutation in *PTEN.*Somatic truncations in either *BRCA1, BRCA2*, or *PTEN* or a pathogenic missense mutation in *PTEN* AND

Somatic truncation in any of the 13 HRR genes or pathogenic mutation in *PTEN* as long this mutation was not applied to satisfy in the antecedent clause.

Pathogenic missense mutations in *PTEN* were defined as those annotated by OncKB as shown on cBioPortal and incorporated into the criteria, given their previously demonstrated association with *POLE*-mutated cancers ([@R26]--[@R28]). The CRC subset of the TCGA PanCancer analysis was used as the discovery cohort. The UCEC subset of the TCGA PanCancer analysis and MSKCC Metastatic CRC Cohort were used as validation cohorts. Somatic signature analysis of whole-exome data from TCGA tumors was performed to ascertain true positives of Polε subtypes (see the Statistical Analysis section). In the MSKCC cohorts, samples were already annotated with Polε subtypes in the metadata through similar somatic signature analyses previously performed. The use of *RAD51B* was omitted from the classifier in analysis of tumors from the DFCI-OncoPanel-3 cohort, given its exclusion in the sequencing panel. Sequence data from all other 13 genes in the classifier were available for the other data sets analyzed from AACR GENIE.

*Saccharomyces cerevisiae* strains and mutation rate measurements {#s2-3}
-----------------------------------------------------------------

Mutations analogous to those found in tumor specimens were made in the *POL2* gene encoding the catalytic subunit of *S. cerevisiae* Polε. The mutations were created in the *URA3*-based integrative plasmid YIpDK1 containing the wild-type *POL2* fragment ([@R29]) by site-directed mutagenesis. To construct haploid *pol2* mutants, the PSD93 diploid (*MAT*a*/MATα ade5-1/ade5-1 lys2:InsE*~*A14*~*/lys2:InsE*~*A14*~ *trp1-289/trp1-289 his7-2/his7-2 leu2-3,112/leu2-3,112 ura3-52/ura3-52* ([@R30])) was transformed with the linearized YIpDK1-pol2-x plasmid to target integration of the plasmid into the chromosomal *POL2*. In the resulting diploids, one *POL2* locus is intact, and the other contains the *URA3* marker between a full-length *pol2-x* allele and a truncated copy of *POL2* without the mutation. These diploids were then sporulated, and Ura^+^ haploids containing the *pol2-x* allele were obtained by tetrad dissection. The *URA3* marker was lost through selection on media containing 5-fluoroorotic acid, and clones that retained the full-length *pol2-x* allele were identified by DNA sequencing. The rate of spontaneous mutation was measured by fluctuation analysis as described previously ([@R25]).

Statistical Analysis {#s2-4}
--------------------

Somatic mutational signatures were calculated from whole-exome sequencing data processed by the Mutect2 somatic variant caller ([@R31]). Mutect2-processed VCF files of TCGA samples were downloaded from the National Cancer Institute Genomic Data Commons and analyzed through a non-negative matrix factorization algorithm to decompose mutational spectra. The DeconstructSigs package in R version 3.3 was used to compare components in the context of the 30 reference signatures identified from the Wellcome Trust Sanger Institute Mutational Signature Framework ([@R32],[@R33]). Wellcome Trust Sanger Institute signature 10 has been previously demonstrated to characterize Polε hypermutation (strand bias for C\>A mutations at TpCpT context and T\>G mutations at TpTpT context), whereas signature 14 describes hypermutation of unknown etiology in a small subset of ECs. Signatures 6, 15, 20, and 26 have been associated with mismatch repair deficiency. Fraction of somatic alterations accounted by each signature was calculated for each tumor sample, and subtype was ascribed to the largest representative signature. Signature 10 analyses for MSKCC samples (Polε subtype) have been precalculated by similar methodologies and have been directly deposited into cBioPortal metadata ([@R34]).

The performance of the classifier was analyzed in the context of the MSS tumors present in each cohort. The statistical significance of differences of mutation rates in yeast was assessed using the Mann-Whitney-Wilcoxon nonparametric tests.

RESULTS {#s3}
=======

Mutation profiles associated with somatic *BRCA1/2* truncations {#s3-1}
---------------------------------------------------------------

The clinical characteristics of the 4 genomic cohorts initially analyzed are described in Table [1](#T1){ref-type="table"}. In the TCGA CRC PanCancer and the MSKCC metastatic CRC cohorts, 3.9% (21/533) and 3.7% (41/1,099) of samples harbored somatic truncating mutations (nonsense, splice site, or frameshift) in *BRCA1/2*, respectively (Figure [1](#F1){ref-type="fig"}a). In the TCGA UCEC PanCancer and MSKCC EC cohorts, 8.2% (42/515) and 2.7% (5/188) of samples had *BRCA1/2* truncations, respectively. Mutational signature analysis of *BRCA1/2-*truncated tumors from the TCGA cohorts demonstrated that 85.7% of such CRCs showed hypermutant signatures (38.1% Polε subtype, 47.6% MSI-H), and 95.3% of such ECs (54.8% Polε subtype, 40.5% MSI-H). Among the published MSKCC cohorts, 78% of the *BRCA1/2*-mutated CRCs demonstrated either known pathogenic Polε exonuclease mutations (14.6%) or MSI (63.4%). All 5 *BRCA1/2-*mutated tumors in the EC cohort exhibited MSI-H phenotypes. Among MSI-H tumors, frameshift mutations were more common than nonsense and splice site mutations.

###### 

Characteristics of the genomic cohorts analyzed

![](ct9-11-e00149-g001)

![Mutational profiles associated with *BRCA1/2* truncations in colorectal and endometrial cancers. (**a**) Hypermutator signatures associated with *BRCA1/2* truncations in colorectal and endometrial cancers. (**b**) Co-occurring mutations in homologous recombination repair genes present in *BRCA1/2*-mutated colorectal cancers and endometrial cancers from the TCGA PanCancer analysis. MSI-H, microsatellite unstable; MSKCC, Memorial Sloan Kettering Cancer Center; TCGA, The Cancer Genome Atlas.](ct9-11-e00149-g002){#F1}

Exome-wide survey of the other somatic mutations present in TCGA *BRCA1/2-*mutated CRC and EC demonstrated co-occurring truncations in additional HRR genes and frequent, pathogenic missense variants in *PTEN* (Figure [1](#F1){ref-type="fig"}b).

Fourteen-gene classifier to identify microsatellite stable hypermutators {#s3-2}
------------------------------------------------------------------------

Given the hypermutant profiles exhibited in *BRCA1/2*-truncated tumors and frequent co-occuring HRR gene mutations, we subsequently devised a classifier to identify MSS hypermutators using *POLE* and 13 HRR genes routinely tested in germline cancer predisposition and/or PARP inhibitor sensitivity assays. We used MSS tumors from the TCGA CRC PanCancer cohort as our discovery data set. The MSKCC metastatic CRC cohort and the TCGA UCEC PanCancer cohort were used as validation data sets. The endometrial MSKCC data set was excluded, given the paucity of MSS hypermutators.

The classifier demonstrated a true-positive rate (TPR) of 100% and a false-positive rate (FPR) of 0% in the discovery data set. The TPR/FPR for each HRR gene in the discovery cohort can be seen in Figure [2](#F2){ref-type="fig"}, and the performance of each criterion in the classifier in Table [2](#T2){ref-type="table"}. Notably, criterion 3, which only requires 2 qualifying mutations in HRR irrespective of Polε status, demonstrated a TPR of 75% and a FPR of 0%.

![Performance of each individual homologous recombination repair gene for identifying microsatellite stable hypermutators in the discovery cohort. Any pathogenic mutation in *PTEN* was considered and highlighted in blue, whereas truncating mutations (nonsense, splice site, and frameshift) were only considered for the other homologous recombination repair genes. The discovery cohort was composed of microsatellite stable colorectal cancers from the TCGA PanCancer data set. TCGA, The Cancer Genome Atlas.](ct9-11-e00149-g003){#F2}

###### 

Performance of each criterion from the classifier in the discovery cohort

![](ct9-11-e00149-g004)

The performance of the classifier among discovery and validation cohorts is presented in Table [3](#T3){ref-type="table"}. In the MSKCC metastatic CRC validation data set, the TPR of the classifier was 100% (7/7), and the FPR was 0.11% (1/948). The positive predictive value was 87.5%, and the negative predictive value was 100%. In the TCGA UCEC PanCancer data set, the TPR was 98.0% (48/49), and the FPR was 0.63%. In this cohort, the positive predictive value was 96.0%, and the negative predictive value was 99.7%. All false positives ([@R3]) in the validation cohorts had no pathogenic exonuclease domain mutation in *POLE*, but demonstrated concurrent pathogenic mutations in *PTEN* and truncations in *ATM*. The performance of each criterion among the validation data sets is presented in Table [4](#T4){ref-type="table"}.

###### 

Performance of a 14-gene classifier to identify microsatellite stable hypermutators

![](ct9-11-e00149-g005)

###### 

Performance of each criterion from the classifier in the validation cohort

![](ct9-11-e00149-g006)

Disambiguation of *POLE* variants of unknown significance and identification of hypermutators without exonuclease mutations {#s3-3}
---------------------------------------------------------------------------------------------------------------------------

The classifier was able to correctly identify 1 hypermutant CRC with a Polε mutational signature in the discovery cohort without somatic alteration in the exonuclease domains of *POLE* or *POLD1.* The tumor harbored truncations in multiple HRR genes: *ATM, ATR, BRCA2,* and *MRE11A.* Furthermore, all tumors with a *POLE* VUS in the exonuclease domain and a qualifying mutation in 1 of 13 HRR genes were accurately classified as having a Polε mutational signature (see Table, Supplementary Digital Content 1, <http://links.lww.com/CTG/A238>). Given the performance of the classifier in the discovery and validation cohorts, we next hypothesized that the classifier could serve to disambiguate VUS as pathogenic and identify additional hypermutators without known exonuclease mutations. To confirm this hypothesis, we analyzed additional clinical cohorts (N = 1,439) from the AACR Project GENIE version 5.0.

Given the lack of MSI status information in AACR Project GENIE, we selected all tumors with nonsynonymous mutation counts that were equal to or higher than the tumor with the lowest mutation count harboring a known pathogenic Polε mutation (Figure [3](#F3){ref-type="fig"}a and see Table, Supplementary Digital Content 2, <http://links.lww.com/CTG/A239>). Tumors harboring mutations associated with MSI or demonstrating overlap with MSKCC samples already analyzed were removed ([@R23]). Application of the classifier resulted as positive for all MSS hypermutant samples (34/34), including 5 with Polε VUS in the exonuclease domain and 2 without somatic Polε exonuclease mutations. Thus, the classifier increased the number of identified MSS hypermutant tumors by 26% over a strategy of using known pathogenic *POLE* mutations.

![Identification of hypermutators without Polε exonuclease domain mutations and disambiguation of variants of unknown significance. (**a**) Application of the classifier to colorectal and endometrial cancer cohorts from the AACR GENIE project. All tumors with mutation counts ≥ tumors with a known pathogenic exonuclease domain mutation were analyzed. The classifier correctly identified all hypermutators without features of microsatellite instability including those with variants of unknown significance and those without detectable exonuclease mutations. (**b**) Somatic signature analysis of exomes from microsatellite stable cancers with Polε A456P and M295R demonstrates hypermutation in all tumors where such mutations are found. (**c**) Fold increase in various measures of the mutation rate by *in vivo* modeling of Polε A456P and M295R mutations in yeast. AACR, American Association for Cancer Research; GENIE, Genomics Evidence Neoplasia Information Exchange.](ct9-11-e00149-g007){#F3}

The most frequent VUS associated with a positive classification in all cohorts was the A456P mutation. Previous studies have inferred that this mutation might be pathogenic due to its location in the exonuclease domain and occurrence in Polε hypermutated tumors ([@R28],[@R35]--[@R37]). However, no functional *in vitro* or *in vivo* assays have been performed to confirm its ability to impair DNA proofreading or elevate the mutation rate. Accordingly, ClinVar has designated the variant as of unknown significance. We performed mutational signature analyses of exomes from all Polε A456P-mutated cancers in TCGA, irrespective of tumor type. All tumors (4/4) bore signatures consistent with hypermutation (Figure [3](#F3){ref-type="fig"}b). For direct *in vivo* confirmation, we modeled this mutation in yeast and determined its effect on the mutation rate. The amino acid sequence around alanine 456 is highly conserved between human and yeast Polε with the exception of 3 residues that include alanine 456 itself (serine in yeast), threonine 454, and threonine 457 (see Figure, Supplementary Digital Content 3, <http://links.lww.com/CTG/A240>). We first constructed a yeast strain in which the entire 454--457 amino acid segment (HLSE) was replaced with the corresponding human sequence (TLAT) to mimic the wild-type human Polε. We then introduced a mutation to replace the alanine in the TLAT sequence with a proline to mimic A456P. The mutation rate was measured using 3 different reporter assays. The *CAN1* forward mutation reporter detects a variety of single-base substitutions, frameshifts, and larger rearrangements that inactivate the gene. The *his7-2* reversion reporter scores predominantly +1 frameshifts. The *lys2-InsE*~*A14*~ reporter allele scores frameshift mutations in a long homonucleotide run, thus providing a readout for MSI. The HLSE-to-TLAT substitution did not affect mutagenesis in any of the assays. The A456P mimic increased the rate of *CAN1* mutation and *his7-2* reversion 3.7-fold and 4.6-fold, respectively, compared with wild type and did not affect instability at the *lys2-InsE*~*A14*~ locus (Figure [3](#F3){ref-type="fig"}C and see Table, Supplementary Digital Content 4, <http://links.lww.com/CTG/A241>), consistent with the hypermutator MSS phenotype of A456P tumors. To further validate our classifier\'s ability to resolve VUS, we selected an additional VUS (M295R) from a TCGA UCEC sample successfully identified as hypermutant by our classifier. Modeling of the M295R mutation in yeast demonstrated a 16- and 19-fold increase in the mutation rate over wild type at the *CAN1* and *his7-2* loci, respectively, with a minimal effect on the instability of the *lys2- InsE*~*A14*~ homonucleotide run.

DISCUSSION {#s4}
==========

In this study, we demonstrate an unexpected finding that somatic truncations in *BRCA1/2* and other HRR genes are highly specific for hypermutator phenotypes in CRC and EC. Although previous studies have observed small increases in tumor mutation burden for other solid tumor types with somatic mutations in HRR genes, no previous association with hypermutation has been reported ([@R38]). We leveraged this novel association to develop and validate a 14-gene classifier for MSS hypermutators through the analysis of publicly available cohorts. Furthermore, we used the sensitivity and specificity of the classifier to formally disambiguate VUS in *POLE* and identify MSS hypermutators without any detectable exonuclease domain mutations. Through analysis of additional genomic cohorts, our classifier identified an additional 26% more MSS hypermutant cancers over the existing strategy of testing for known pathogenic *POLE* mutations.

It should be noted that the MSS hypermutant tumors identified without exonuclease domain mutations still demonstrated *POLE-*mutated signatures; these tumors harbored strand bias for C\>A mutations at TpCpT context and T\>G mutations at TpTpT context. The lack of missense exonuclease domain mutations in these tumors may suggest the existence of alternative genetic mechanisms of how the proofreading ability of *POLE* may be disrupted. For example, current gene sequencing strategies often fail to detect mutations in deep intronic segments that may cause aberrant splicing events of the exonuclease domain. Alternatively, pathogenic missense mutations may be miscalled, given that no tumor variant calling algorithm demonstrates perfect accuracy ([@R39]).

This study highlights the continued importance of interrogating tissue specificity for pharmacogenomic associations. The promulgation of molecular basket trials, where the effect of 1 drug on a single mutation is evaluated in a variety of tumor types at the same time, has changed the paradigm of clinical trials in precision oncology. Our work reinforces the additional importance of global assessments of tumor mutations in therapy decisions. Analyses of single gene mutations in the broader context of exome-wide signatures enabled us to postulate a novel pharmacogenomic association of HRR genes with immunotherapy. Moreover, this analysis could only be performed thanks to the commitment of academic institutions and nonprofit organizations to share genomic data sets to the wider scientific community.

Immune checkpoint blockade has advanced the treatment of CRC and EC with high neoantigen loads, particularly those tumors with MSI ([@R9],[@R10]). Accounting for ∼2% of CRCs and 7% of ECs, MSS hypermutant tumors often demonstrate neoantigen burdens that exceed those of MSI-H tumors and have also demonstrated robust responses to immune checkpoint blockade and survival advantages ([@R11]--[@R14],[@R40]--[@R43]). Despite these observations, identification of MSS hypermutant cancers for clinical trial recruitment and palliative immunotherapy remains challenging. The absence of a low-cost, comprehensive screening test and the lower prevalence of MSS hypermutant tumors than MSI-H tumors contribute to their underrecognition and undertreatment in the clinical environment. To address this issue, we intentionally selected genes in our classifier that are routinely tested in panels performed by many medical centers. Furthermore, the nature of the criteria also allows for medical providers to scale down the number of HRR genes sequenced (as long as a minimum *PTEN*, *BRCA1,* and *BRCA2* are incorporated) for an acceptable trade-off in sensitivity, yet without compromising specificity.

Although we analyzed multiple cohorts that have been previously deemed suitable for US Food and Drug Administration applications for accompanying diagnostics, future prospective trials and cost-effective analyses will be required to further demonstrate the clinical utility of our classifier as a comprehensive, low-cost alternative to tumor mutation burden testing for immunotherapy in these cancer types.
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